6505--Abiraterone Tablets

The Department of Veterans Affairs National Acquisition Center is seeking proposals for Abiraterone Acetate 250mg Tablets in 120-tablet bottles through an unrestricted competitive solicitation. The contract will supply multiple federal agencies including VA, DoD, Indian Health Service, Bureau of Prisons, Federal Health Care Center, and State Veterans Homes through Pharmaceutical Prime Vendor (PPV) Programs. Key contract requirements include meeting FDA Good Manufacturing Practice standards, implementing bar coding and Drug Supply Chain Security Act compliance, and submitting quarterly sales reports with a 0.50% Cost Recovery Fee. Offerors must be prepared to establish PPV distribution agreements within a 60-day maximum implementation period after award. The final proposal due date is January 13, 2025, at 2:30 PM CST, with two prior amendments having modified the original submission timeline.

The solicitation is an unrestricted competition targeting pharmaceutical manufacturers in the NAICS 325412 category, with anticipated annual quantities of 71,997 bottles per year. The contract structure includes one base year and four one-year option periods, suggesting a potential five-year total contract duration. Specific packaging requirements mandate safety caps, a minimum 120cc bottle volume, and precise label dimensions. While no specific set-aside designations are noted, the procurement will result in a single award covering the base year and all optional years. The contract will facilitate distribution through established Pharmaceutical Prime Vendor Programs, enabling efficient nationwide access for participating federal healthcare institutions. Contractors must demonstrate capability to meet stringent pharmaceutical manufacturing and distribution standards while maintaining regulatory compliance across multiple federal healthcare systems.